Xact Kapitalforvaltning AB Grows Holdings in SAGE Therapeutics Inc (SAGE)

Xact Kapitalforvaltning AB grew its holdings in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 12.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,044 shares of the biopharmaceutical company’s stock after buying an additional 900 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in SAGE Therapeutics were worth $771,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in SAGE. FMR LLC grew its holdings in shares of SAGE Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 6,999,644 shares of the biopharmaceutical company’s stock worth $988,700,000 after purchasing an additional 22,266 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of SAGE Therapeutics by 6.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares in the last quarter. Vanguard Group Inc grew its holdings in shares of SAGE Therapeutics by 6.9% during the 3rd quarter. Vanguard Group Inc now owns 4,085,812 shares of the biopharmaceutical company’s stock worth $577,121,000 after purchasing an additional 262,990 shares in the last quarter. BlackRock Inc. grew its holdings in shares of SAGE Therapeutics by 0.9% during the 3rd quarter. BlackRock Inc. now owns 2,816,410 shares of the biopharmaceutical company’s stock worth $397,818,000 after purchasing an additional 23,862 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock worth $244,898,000 after purchasing an additional 110,134 shares in the last quarter.

A number of brokerages have recently issued reports on SAGE. BidaskClub upgraded SAGE Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 5th. Wolfe Research started coverage on SAGE Therapeutics in a research note on Friday, December 14th. They set an “outperform” rating for the company. ValuEngine cut SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. JPMorgan Chase & Co. set a $205.00 target price on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, Cowen reaffirmed a “buy” rating and set a $207.00 target price on shares of SAGE Therapeutics in a research note on Thursday, November 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $200.58.

In related news, Director James M. Frates sold 7,500 shares of SAGE Therapeutics stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $134.81, for a total transaction of $1,011,075.00. Following the sale, the director now directly owns 11,735 shares in the company, valued at $1,581,995.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Stephen Kanes sold 22,948 shares of SAGE Therapeutics stock in a transaction on Friday, February 8th. The stock was sold at an average price of $150.00, for a total value of $3,442,200.00. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

SAGE Therapeutics stock traded down $0.90 during mid-day trading on Monday, reaching $150.88. 2,250 shares of the company’s stock were exchanged, compared to its average volume of 496,123. The firm has a market capitalization of $7.10 billion, a P/E ratio of -21.33 and a beta of 2.93. SAGE Therapeutics Inc has a one year low of $79.88 and a one year high of $188.82.

COPYRIGHT VIOLATION WARNING: “Xact Kapitalforvaltning AB Grows Holdings in SAGE Therapeutics Inc (SAGE)” was first reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.wkrb13.com/2019/02/11/xact-kapitalforvaltning-ab-grows-holdings-in-sage-therapeutics-inc-sage.html.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

See Also: Discover Your Risk Tolerance

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply